Pregnancy Risk Category B
How supplied
Tablets: 250 mg
Action
Unknown. An antiplatelet that probably blocks adenosine diphosphate-induced platelet-to-fibrinogen and platelet-to-platelet binding.
Indications & dosage
To reduce risk of thrombotic stroke in patients with history of stroke or who have experienced stroke precursors--
Adults: 250 mg P.O. b.i.d. with meals.
Adverse reactions
CNS: dizziness, peripheral neuropathy.
CV: vasculitis.
EENT: conjunctival hemorrhage.
GI: diarrhea, nausea, dyspepsia, abdominal pain, anorexia, vomiting, flatulence, bleeding.
GU: hematuria, dark-colored urine.
Hematologic: neutropenia, pancytopenia, agranulocytosis, immune thrombocytopenia.
Hepatic: abnormal liver function tests.
Musculoskeletal: arthropathy, myositis.
Respiratory: allergic pneumonitis.
Skin: rash, pruritus, ecchymoses, maculopapular rash, urticaria, thrombocytopenic purpura.
Other: hypersensitivity reactions, postoperative bleeding.
Interactions
Drug-drug. Antacids: decreased plasma ticlopidine levels. Separate administration times by at least 2 hours.
Aspirin: effects of aspirin on platelets potentiated. Avoid concomitant use.
Cimetidine: decreased clearance of ticlopidine and increased risk of toxicity. Avoid concomitant use.
Digoxin: slight decrease in serum digoxin levels. Monitor serum digoxin levels.
Phenytoin: possible elevation in serum phenytoin level. Monitor closely.
Theophylline: decreased theophylline clearance and risk of toxicity. Monitor closely and adjust theophylline dosage as ordered.
Drug-herb. Red clover: possible increased risk of bleeding. Use together cautiously.
Effects on diagnostic tests
A positive antinuclear antibody titer has been reported rarely.
Contraindications
Contraindicated in patients with hypersensitivity to drug and in those with severe hepatic impairment, hematopoietic disorders, active pathologic bleeding from peptic ulceration, or active intracranial bleeding.
Nursing considerations
Patient teaching
*Liquid contains alcohol. **May contain tartrazine. †Canada ‡Australia §U.K. OTCOver the counter
Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING